
PBH Stock Forecast & Price Target
PBH Analyst Ratings
Bulls say
Prestige Consumer Healthcare's stock outlook appears positive due to an increased EBITDA estimate for 2026 and 2027 by approximately $15 million, reflecting higher anticipated sales growth. The company's diverse portfolio, which includes well-established brands like Clear Eyes and Dramamine, is supported by strong organic volume growth expected to accelerate in the latter half of 2025, driven by significant product launches and improved production capacities. Additionally, the company is witnessing positive same-store sales (SSS) trends in both the U.S. and Canada, indicating strengthening consumer demand and potential for further revenue growth.
Bears say
The negative outlook on Prestige Consumer's stock is underpinned by expectations of lower-than-expected revenue growth and potential EBITDA margin compression due to persistent increases in input costs. The company faces significant risks from a weaker operating environment in its primary markets, compounded by challenges such as high material costs and limited acquisition opportunities. Additionally, the need for effective deleveraging is pressing, with high levels of debt potentially hindering financial flexibility in the near future.
This aggregate rating is based on analysts' research of Prestige Brands Holdings and is not a guaranteed prediction by Public.com or investment advice.
PBH Analyst Forecast & Price Prediction
Start investing in PBH
Order type
Buy in
Order amount
Est. shares
0 shares